

Hematologic

Mel (86519, #5910) / Melissa (88434, #0483)

Malignant Heme

Leukemia/Lymphoma:

IRB #H-37452/ LCCC #1637: Brentuximab Vedotin w/ Cyclophosphamide, Doxorubicin, Etoposide, & Prednisone (BV-CHEP) for Adult T-Cell Leukemia/ Lymphoma: A Ph II Trial - Sloan

IRB # H-38532/ AMC #101: Pilot Study of Ibrutinib & R-da-EPOCH for Front Line Tx of AIDS-Related Lymphomas – Sloan; Mel / Anthony A (45729, #0402)

CIRB #H-39514/ SWOG #S1826: Ph III, Rand. Study of Nivo + AVD or Brentuximab Vedotin + AVD in Newly Dx Advanced Stage Classical Hodgkin Lymphoma - Sloan

IRB #H-39342/ DFCI #18-089: Ph I/II Study of Duvelisib & Venetoclax in Relapsed/Refractory CLL, SLL, or Richter's Syndrome - Sloan

Multiple Myeloma:

CIRB #H-39488/ SWOG S1803 (DRAMMATIC): Ph III Study of Daratumumab + Lenalidomide or Lenalidomide as Post-ASCT Maintenance in MM Using MRD to Direct Tx Duration - Sanchorawala

WIRB #H-40731/ AbbVie #M13-494: Ph 3, Rand. Study of Venetoclax + Dex v Pom + Dex in t(11;14)+ Relapsed/Refractory MM - Edwards

IRB #H-39242/ DFCI #19-291 (IxaPomDex): Ph I/II Study of Twice Weekly Ixazomib + Pomalidomide + Dex in Relapsed/Refractory MM – Sanchorawala

Benign Heme

Primary Immune Thrombocytopenia:

Advarra IRB #H-41733/ Takeda #TAK-079: Ph 2, Rand., Dble-Blnd, Placebo-Ctrl Study to Eval. Safety, Tolerability, & Efficacy of TAK-079 in Persistent/Chronic ITP - Sloan (pending)

Sickle Cell

Mel (86519, #5910) / Anthony A (45729, #0402)

Central IRB #H-39846/ NHLB #SCD-CARRE: Sickle Cell Disease & Cardio-vAscular Risk - Red cell Exchange Trial - Klings

Advarra IRB #H-40856/ Forma #4202-HEM-301 (HIBISCUS): Adaptive, Rand., Placebo-Ctrl, Dbl-blind, Study of Oral FT-4202, a Pyruvate Kinase Agonist in Pts w/ Sickle Cell Disease - Klings

Program Contacts

Matthew Kulke, MD: (617) 638-7002

Anthony Shelton, RN: (617) 638-5612, Pager: 6631

Kiana Mahdavian, PhD: (617) 638-7599

Clinical Research Nurses

Mel Migre, RN: (617) 638-6519, Pager: 5910

Alex Hern, RN: (617) 638-7513, Pager: 5912

Faniela Louis, RN: (617) 638-8274, Pager: 0045

Clinical Research Coordinators

Annie Jose: (617) 638-8213, Pager: 0511

Liz Pottier: (617) 638-8260, Pager: 0120

Anthony Akinbami: (617) 414-5729, Pager: 0402

Sarah Ebhodaghe: (617) 638-7559, Pager: 8956

Melissa Difuntorum: (617) 638-8434, Pager: 0483

David Li (TRC): (617) 638-7511, Pager: 3047

Adrian Ilinski (TRC): (617) 638-7514, Pager: 6316

Samhita Joshi (TMIST): (617) 414-4974

Nick Dang: (617) 638-8273

Priya Gupta Vajrapu: (617) 638-6521

Links

NCI Cancer Trials Support Unit: [CTSU.org](http://www.ctsu.org)

SWOG Oncology: [SWOG.org](http://www.swog.org)

NRG Oncology: <http://www.nrgoncology.org>

Amyloid Center: <http://www.bu.edu/amyloid/>



EXCEPTIONAL CARE. WITHOUT EXCEPTION.

Cancer & Hematology Clinical Research Program



Active Clinical Trials

February 2022

<http://www.bumc.bu.edu/clinicaltrials>



650 Albany St, EBRC-4
Boston, MA 02118
(617) 638-8265

Breast

Alex (87513, #5912) / Liz (88260, #0120)

CIRB #H-37507 CTSU #A011202: A Rand. Ph III Trial of ALND v Axillary RT in Breast Ca Pts w/ (+) Sentinel LN Dz After NAC - *Cassidy*

IRB #H-39510/ DFCI #17-101 (PACE): Palbociclib After CDK & Endocrine Tx (PACE): A Rand. Ph II Study of Fulvestrant, Palbociclib, & Avelumab for Endocrine Pre-tx ER+/HER2- Met, Breast Ca - *Ko*

CIRB #H-40381 CTSU #EA1181 (CompassHER2-pCR): Preop THP & Postop HP in Pts w/ Path. CR – *Ko*

IRB #H-42223/ DFCI #19-239: Ph 1b/2 Study to Eval. Safety & Anti-Tumor Activity of Sacituzumab Govitecan + Talazoparib in Met. Triple-Negative Breast Ca - *Ko* (**pending IRB approval**)

Cutaneous

Mel (86519, #5910) / Liz (88260, #0120)

Melanoma:

CIRB #H-38640/ SWOG #S1801: Ph II Rand. Study of Adjuvant vs Neoadjuvant Pembro for Clinically Detectable St III-IV Melanoma – *Lerner*

CIRB #H-41279/ CTSU #EA6192 (PET-Stop): Ph II Study of Biomarker Driven Early D/c of Anti-PD-1 Therapy in Advanced Melanoma – *Lerner* (**pending**)

Kaposi Sarcoma:

CIRB #pend/ AMC #108: Multicenter Ph II Study of Pomalidomide Monotherapy in Kaposi Sarcoma – *Lerner* (**not yet submitted to IRB**)

Gastrointestinal

Alex (87513, #5912) / Sarah (87559, #8956)

Colorectal:

CIRB #H-37277/ CTSU #A021502: Rand. trial of standard chemo +/- Atezolizumab as adjuvant tx for dMMR St III colon cancer - *Addo-Tabiri*

CIRB #H-39558/ CTSU #A021703 (SOLARIS): Rand. Dbl-Blnd Ph III Trial of Vitamin D3 in Untreated Metastatic Colorectal Ca - *Addo-Tabiri*

Neuroendocrine:

CIRB #H-38045/ CTSU #A021602 (CABINET): Rand. Dbl-Blnd Ph III Study of Cabozantinib vs Placebo in Advanced Neuroendocrine Tumors after Progression on Prior Therapy - *Kulke*

WCG IRB #H-41709/ DFCI #19-403: Ph II trial of cabozantinib + nivolumab for advanced carcinoid tumors - *Kulke*

NEIRB #H-40767/ ITM #LET (COMPETE): Rand. Ph III Study of PRRT w/ 177Lu-Edotreotide vs Everolimus in Inoperable, Progressive, SSTR+, GEP-NETs - *Kulke* (**pending**)

Hepatobiliary:

HIRB #2019-51/ Merck #KEYNOTE 937: Ph 3 Dble-Blnd Study of Pembro v Placebo as Adjuvant Tx in Pts w/ HCC & Complete Radiological Response after Surgical Resection or Ablation - *Marks*

IRB #H-42011 / HCRN #GI10-405: Rand. Ph III Study of Atezo + Bev w/ Y-90 Unresectable HCC - *Marks* (**pending**)

Anal:

CIRB #H-39855/ CTSU #EA2182 (DECREASE): A Rand. Ph II Study of De-Intensified ChemoXRT for Early-Stage Anal SCC – *Mak*

Pancreatic:

CIRB #H-40808/ CTSU #A021806: A Ph III Trial of Peri-op vs Adjuvant Chemo for Resectable Pancreatic Cancer – *Sachs*

Genitourinary

Faniela (8274, #0045) / Liz (88260, #0120)

Prostate:

CIRB #H-37226/ NRG #GU005: Ph III IGRT & SBRT vs IGRT & Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer - *Hirsch*

Head & Neck

Mel (86519, #5910) / Sarah (87559, #8956)

Head & Neck SCC:

CIRB #H-32379/ RTOG #R1216: Rand. Ph II/III Trial of Adjuvant RT w/ Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in High-Risk SCC of the H&N - *Truong*

CIRB #H-41338/ NRG #HN006: Rand. Ph II/III Trial of Sentinel Lymph Node Biopsy v Elective Neck Dissection for Early-Stage Oral Cavity Cancer - *Truong*

CIRB #H-37278/ NRG #HN004: Rand. Ph II/III Trial of RT + Concurrent Durva vs. RT + Concurrent Cetuximab in Locoregionally Advanced H&N Cancer w/ Contraindication to Cisplatin – *Truong* (**temp closure**)

IRB #H-38134/ RTOG Foundation #R3507: A Rand. Ph II study of Pembro + SBRT Re-Irradiation v SBRT Alone for Locoregionally Recurrent or 2nd Primary H&N Ca – *Truong* (**temp closure**)

CIRB #H-39827/ NRG #HN005: Rand. Ph II/III Trial of De-Intensified RT for Early-Stage, p16+, Non-Smoking Assoc. Oropharyngeal Cancer - *Truong* (**pending**)

Nasopharyngeal:

CIRB #H-33148/ NRG #HN001: Rand. Ph II & III Studies of Tx for Nasopharyngeal Ca Based on Epstein Barr Virus (EBV) DNA - *Truong*

Lung

Faniela (8274, #0045) / Sarah (87559, #8956)

NSCLC:

CIRB #H-33418/ CTSU #A151216 (ALCHEMIST): Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial - *Everett*

CIRB #H-40717/ CTSU #A081801 (ACCIO): Integration of Immunotherapy into Adjuvant Tx for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO) – *Tapan* (**temp closure**)

CIRB #H-33425/ CTSU #E4512: A Ph III Trial for Resected Early Stage NSCLC: Crizotinib v Obs. for Pts w/ Tumors ALK+ - *Everett*

CIRB #H-36723/ NRG #LU002: Maintenance Systemic Tx vs Local Consolidative Tx (LCT) + Maintenance Systemic Tx for Limited Met. NSCLC: Rand. Ph II/III Trial – *Mak* (**temp closure**)

WIRB #H-40344/ DFCI #19-523: Pilot study of serial plasma genotyping to guide tx of advanced NSCLC receiving 1st-line pembro - *Tapan*

CIRB #H-40842/ CTSU #EA5181: Rand. Ph III Trial of Durvalumab as Concurrent + Consolidative Tx or Consolidative Tx Alone for Unresectable St 3 NSCLC - *Tapan*

Cop. IRB #H-40633/ EMD Serono #MS-0031 (INSIGHT 2): Ph II, Study of Tepotinib + Osimertinib in MET Amplified Advanced/Met. NSCLC w/ EGFR Mutations & Acquired Resistance to Prior Osimertinib - *Tapan*

WIRB #H-40642/ Janssen #NSC1001: Ph 1/1b Study to Evaluate Safety & PKs of JNJ-73841937 (Lazertinib), alone or w/ JNJ-61186372, an EGFR & cMet Antibody in Advanced NSCLC - *Tapan*

SCLC:

CIRB #H-40325/ SWOG S1827 (MAVERCK): MRI Brain Surveillance Alone vs MRI Surveillance + PCI: A Rand. Ph III Trial in SCLC - *Mak*

CIRB #H-41197/ NRG #LU007 (RAPTOR): Rand. Ph II/III Trial of Consolidation RT + IO for ES-SCLC: RAPTOR trial - *Tapan*

CIRB #H-42287/ NRG #CC009 Ph III Trial of SRS vs HA-WBRT for ≤10 Brain Mets from SCLC – *Mak* (**pending**)

Esophageal:

CIRB #H-42109/ CTSU #EA2174: Ph II/III Study of Peri-op Nivo + Ipi in Locoregional Esophageal & GEJ Adeno - *Assi* (**pending**)

Amyloidosis

Mel (86519, #5910) / Melissa (88434, #0483)

IRB #H-35835/ BMC #Evomela: A Ph II Open-Label, Safety & Efficacy Study of Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Pts Undergoing ASCT – *Sloan*; *Faniela* (88247, #0045)

WIRB #H-39485/ Caelum Bio #CAEL-101 301: Ph 3, Dbl-Blnd, Study of CAEL-101 + Plasma Cell Dyscrasia Tx (PCDT) vs Placebo + PCDT in Tx-Naïve Pts w/ Mayo Stage IIIb AL Amyloidosis - *Santhorawala*

WIRB #H-40375/ Caelum Bio #CAEL-101 302: Ph 3, Dbl-Blnd, Study of CAEL-101 + Plasma Cell Dyscrasia Tx (PCDT) vs Placebo + PCDT in Tx-Naïve Pts w/ Mayo Stage IIIa AL Amyloidosis - *Santhorawala*

IRB #H-39705/ Cornell Janssen DPd: Daratumumab, Pomalidomide & Dex (DPd) in Relapsed/Refractory AL Amyloidosis Pts Previously Exposed to Dara - *Santhorawala*

CIRB #H-42375/ ETCTN #10440: A Phase 1/1a Study of Venetoclax, Ixazomib & Dex for Relapsed/Refractory AL Amyloidosis - *Santhorawala*

WIRB #H-40919/ Sorrento #STI-6129: Ph 1, Dose-Escalation Safety & Efficacy Study of STI-6129 in Relapsed/Refractory Systemic AL Amyloidosis - *Santhorawala*

Advarra IRB #H-41609/ Prothena #NEOD001-301 (AFFIRM AL): Ph 3, Rand., Dble-Blnd, Study of Birtamimab + SOC vs. Placebo + SOC in Mayo St IV AL Amyloidosis - *Santhorawala* (**pending**)

Advarra IRB #H-42313/ Janssen #AMY2009: A Ph 2, Multicohort Study of Daratumumab-Based Tx in AL Amyloidosis - *Santhorawala* (**not yet submitted to IRB**)